Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker
Cancer is a systemic disease involving multiple components produced from both tumor cells themselves and surrounding stromal cells. The pro- or anti-tumoral role of the stroma is still under debate. Indeed, it has long been considered the main physical barrier to the diffusion of chemotherapy by its...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-05-01
|
| Series: | Matrix Biology Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590028520300028 |
| _version_ | 1819133620252573696 |
|---|---|
| author | Sophie Liot Alexandre Aubert Valérie Hervieu Naïma El Kholti Joost Schalkwijk Bernard Verrier Ulrich Valcourt Elise Lambert |
| author_facet | Sophie Liot Alexandre Aubert Valérie Hervieu Naïma El Kholti Joost Schalkwijk Bernard Verrier Ulrich Valcourt Elise Lambert |
| author_sort | Sophie Liot |
| collection | DOAJ |
| description | Cancer is a systemic disease involving multiple components produced from both tumor cells themselves and surrounding stromal cells. The pro- or anti-tumoral role of the stroma is still under debate. Indeed, it has long been considered the main physical barrier to the diffusion of chemotherapy by its dense and fibrous nature and its poor vascularization. However, in murine models, the depletion of fibroblasts, the main ExtraCellular Matrix (ECM)-producing cells, led to more aggressive tumors even though they were more susceptible to anti-angiogenic and immuno-modulators. Tenascin-C (TNC) is a multifunctional matricellular glycoprotein (i.e. an ECM protein also able to induce signaling pathway) and is considered as a marker of tumor expansion and metastasis. However, the status of other tenascin (TN) family members and particularly Tenascin-X (TNX) has been far less studied during this pathological process and is still controversial. Herein, through (1) in silico analyses of the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases and (2) immunohistochemistry staining of Tissue MicroArrays (TMA), we performed a large and extensive study of TNX expression at both mRNA and protein levels (1) in the 6 cancers with the highest incidence and mortality in the world (i.e. lung, breast, colorectal, prostate, stomach and liver) and (2) in the cancers for which sparse data regarding TNX expression already exist in the literature. We thus demonstrated that, in most cancers, TNX expression is significantly downregulated during cancer progression and we also highlighted, when data were available, that high TNXB mRNA expression in cancer is correlated with a good survival prognosis. |
| first_indexed | 2024-12-22T09:50:11Z |
| format | Article |
| id | doaj.art-04a6e181dbf640288abd28da32513823 |
| institution | Directory Open Access Journal |
| issn | 2590-0285 |
| language | English |
| last_indexed | 2024-12-22T09:50:11Z |
| publishDate | 2020-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Matrix Biology Plus |
| spelling | doaj.art-04a6e181dbf640288abd28da325138232022-12-21T18:30:23ZengElsevierMatrix Biology Plus2590-02852020-05-016100021Loss of Tenascin-X expression during tumor progression: A new pan-cancer markerSophie Liot0Alexandre Aubert1Valérie Hervieu2Naïma El Kholti3Joost Schalkwijk4Bernard Verrier5Ulrich Valcourt6Elise Lambert7Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI), UMR CNRS 5305, Université Lyon 1, Institut de Biologie et Chimie des Protéines, 7, passage du Vercors, F-69367 Lyon Cedex 07, FranceLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI), UMR CNRS 5305, Université Lyon 1, Institut de Biologie et Chimie des Protéines, 7, passage du Vercors, F-69367 Lyon Cedex 07, FranceService d'Anatomopathologie, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, FranceLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI), UMR CNRS 5305, Université Lyon 1, Institut de Biologie et Chimie des Protéines, 7, passage du Vercors, F-69367 Lyon Cedex 07, FranceRadboud Institute for Molecular Life Sciences, Faculty of Medical Sciences, 370 Geert Grooteplein-Zuid 26 28, 6525 GA Nijmegen, NetherlandsLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI), UMR CNRS 5305, Université Lyon 1, Institut de Biologie et Chimie des Protéines, 7, passage du Vercors, F-69367 Lyon Cedex 07, FranceLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI), UMR CNRS 5305, Université Lyon 1, Institut de Biologie et Chimie des Protéines, 7, passage du Vercors, F-69367 Lyon Cedex 07, France; Corresponding authorsLaboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI), UMR CNRS 5305, Université Lyon 1, Institut de Biologie et Chimie des Protéines, 7, passage du Vercors, F-69367 Lyon Cedex 07, France; Corresponding authorsCancer is a systemic disease involving multiple components produced from both tumor cells themselves and surrounding stromal cells. The pro- or anti-tumoral role of the stroma is still under debate. Indeed, it has long been considered the main physical barrier to the diffusion of chemotherapy by its dense and fibrous nature and its poor vascularization. However, in murine models, the depletion of fibroblasts, the main ExtraCellular Matrix (ECM)-producing cells, led to more aggressive tumors even though they were more susceptible to anti-angiogenic and immuno-modulators. Tenascin-C (TNC) is a multifunctional matricellular glycoprotein (i.e. an ECM protein also able to induce signaling pathway) and is considered as a marker of tumor expansion and metastasis. However, the status of other tenascin (TN) family members and particularly Tenascin-X (TNX) has been far less studied during this pathological process and is still controversial. Herein, through (1) in silico analyses of the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases and (2) immunohistochemistry staining of Tissue MicroArrays (TMA), we performed a large and extensive study of TNX expression at both mRNA and protein levels (1) in the 6 cancers with the highest incidence and mortality in the world (i.e. lung, breast, colorectal, prostate, stomach and liver) and (2) in the cancers for which sparse data regarding TNX expression already exist in the literature. We thus demonstrated that, in most cancers, TNX expression is significantly downregulated during cancer progression and we also highlighted, when data were available, that high TNXB mRNA expression in cancer is correlated with a good survival prognosis.http://www.sciencedirect.com/science/article/pii/S2590028520300028Tenascin-XCancersmRNA and protein levelsPrognosis markerMeta-analysisTissue MicroArray |
| spellingShingle | Sophie Liot Alexandre Aubert Valérie Hervieu Naïma El Kholti Joost Schalkwijk Bernard Verrier Ulrich Valcourt Elise Lambert Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker Matrix Biology Plus Tenascin-X Cancers mRNA and protein levels Prognosis marker Meta-analysis Tissue MicroArray |
| title | Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker |
| title_full | Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker |
| title_fullStr | Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker |
| title_full_unstemmed | Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker |
| title_short | Loss of Tenascin-X expression during tumor progression: A new pan-cancer marker |
| title_sort | loss of tenascin x expression during tumor progression a new pan cancer marker |
| topic | Tenascin-X Cancers mRNA and protein levels Prognosis marker Meta-analysis Tissue MicroArray |
| url | http://www.sciencedirect.com/science/article/pii/S2590028520300028 |
| work_keys_str_mv | AT sophieliot lossoftenascinxexpressionduringtumorprogressionanewpancancermarker AT alexandreaubert lossoftenascinxexpressionduringtumorprogressionanewpancancermarker AT valeriehervieu lossoftenascinxexpressionduringtumorprogressionanewpancancermarker AT naimaelkholti lossoftenascinxexpressionduringtumorprogressionanewpancancermarker AT joostschalkwijk lossoftenascinxexpressionduringtumorprogressionanewpancancermarker AT bernardverrier lossoftenascinxexpressionduringtumorprogressionanewpancancermarker AT ulrichvalcourt lossoftenascinxexpressionduringtumorprogressionanewpancancermarker AT eliselambert lossoftenascinxexpressionduringtumorprogressionanewpancancermarker |